Tokuchi Yoshimasa相关文献与解析，生知库

Kohya Risako, Suda Goki, Ohara Masatsugu, Hosoda Shunichi, Sho Takuya, Chuma Makoto, Komori Atsumasa, Kugiyama Yuki, Yasui Yutaka, Tsuchiya Kaoru, Kurosaki Masayuki, Tani Joji, Kaneko Shun, Nakagawa Mina, Asahina Yasuhiro, Maekawa Shinya, Enomoto Nobuyuki, Yamamoto Yoshiya, Baba Masaru, Yamada Ren, Sasaki Takashi, Yoda Tomoka, Yoshida Sonoe, Fu Qingjie, Yang Zijian, Maehara Osamu, Ohnishi Shunsuke, Tokuchi Yoshimasa, Kitagataya Takashi, Kawagishi Naoki, Nakai Masato, Natsuizaka Mitsuteru, Ogawa Koji, Sakamoto Naoya

其它

发表日期：2025

文献求助收藏

Laparoscopic Low Anterior Resection for Rectal Cancer in a Patient With Rectal Varices Secondary to Metabolic Dysfunction-Associated Steatohepatitis-Related Cirrhosis: A Case Report

腹腔镜下直肠癌低位前切除术治疗代谢功能障碍相关脂肪性肝炎相关性肝硬化合并直肠静脉曲张患者：病例报告

期刊:Cureus Journal of Medical Science

影响因子:1.3

doi:10.7759/cureus.87057

Yoshida, Takuto; Emoto, Shin; Hosokawa, Yuka; Ota, Takuji; Kato, Koichi; Kikuchi, Hironobu; Kawai, Tomoaki; Tokuchi, Yoshimasa; Takahashi, Norihiko; Taketomi, Akinobu

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.

基线 CXCL9 水平低可预测接受 Atezolizumab 联合 Bevacizumab 治疗的不可切除 HCC 患者的早期疾病进展

期刊:Liver Cancer

影响因子:9.1

doi:10.1159/000527759

Hosoda Shunichi, Suda Goki, Sho Takuya, Ogawa Koji, Kimura Megumi, Yang Zijian, Yoshida Sonoe, Kubo Akinori, Tokuchi Yoshimasa, Kitagataya Takashi, Maehara Osamu, Ohnishi Shunsuke, Nakamura Akihisa, Yamada Ren, Ohara Masatsugu, Kawagishi Naoki, Natsuizaka Mitsuteru, Nakai Masato, Morikawa Kenichi, Furuya Ken, Baba Masaru, Yamamoto Yoshiya, Suzuki Kazuharu, Izumi Takaaki, Meguro Takashi, Terashita Katsumi, Ito Jun, Miyagishima Takuto, Sakamoto Naoya

其它

发表日期：2023

文献求助收藏

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma

肌肉萎缩和皮下脂肪组织放射密度增高同时存在预示着肝细胞癌预后不良。

期刊:Frontiers in Nutrition

影响因子:5.1

doi:10.3389/fnut.2023.1272728

Ohara, Masatsugu; Suda, Goki; Kohya, Risako; Sasaki, Takashi; Yoda, Tomoka; Yoshida, Sonoe; Fu, Qingjie; Yang, Zijian; Hosoda, Shunichi; Maehara, Osamu; Ohnishi, Shunsuke; Tokuchi, Yoshimasa; Kitagataya, Takashi; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Ogawa, Koji; Sakamoto, Naoya

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者对阿特珠单抗联合贝伐珠单抗治疗产生耐药性期间血清生长因子的变化

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers15030593

Yang, Zijian; Suda, Goki; Maehara, Osamu; Ohara, Masatsugu; Yoda, Tomoka; Sasaki, Takashi; Kohya, Risako; Yoshida, Sonoe; Hosoda, Shunichi; Tokuchi, Yoshimasa; Kitagataya, Takashi; Suzuki, Kazuharu; Kawagishi, Naoki; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Ogawa, Koji; Ohnishi, Shunsuke; Sakamoto, Naoya

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.

血清 FGF21 水平变化与 Lenvatinib 诱导的不可切除肝细胞癌患者食欲丧失之间可能存在相关性

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers15123257

Kohya Risako, Suda Goki, Ohara Masatsugu, Sasaki Takashi, Yoda Tomoka, Sakurai Naofumi, Yoshida Sonoe, Fu Qingjie, Yang Zijian, Hosoda Shunichi, Maehara Osamu, Ohnishi Shunsuke, Tokuchi Yoshimasa, Kitagataya Takashi, Suzuki Kazuharu, Kawagishi Naoki, Nakai Masato, Sho Takuya, Natsuizaka Mitsuteru, Ogawa Koji, Sakamoto Naoya

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

血清血管生成素-2可预测丙型肝炎直接抗病毒治疗后肝细胞癌的发生和复发。

期刊:Viruses-Basel

影响因子:3.5

doi:10.3390/v15010181

Kawagishi, Naoki; Suda, Goki; Yamamoto, Yoshiya; Baba, Masaru; Furuya, Ken; Maehara, Osamu; Ohnishi, Shunsuke; Yoshida, Sonoe; Fu, Qingjie; Yang, Zijian; Hosoda, Shunichi; Tokuchi, Yoshimasa; Kitagataya, Takashi; Ohara, Masatsugu; Suzuki, Kazuharu; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Ogawa, Koji; Sakamoto, Naoya

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

阿特珠单抗和贝伐珠单抗治疗不符合 IMbrave150 研究入组标准的不可切除肝细胞癌患者的疗效及对肝功能储备的影响

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers14163938

Sho, Takuya; Suda, Goki; Yamamoto, Yoshiya; Furuya, Ken; Baba, Masaru; Ogawa, Koji; Kubo, Akinori; Tokuchi, Yoshimasa; Fu, Qingjie; Yang, Zijian; Kimura, Megumi; Kitagataya, Takashi; Maehara, Osamu; Ohnishi, Shunsuke; Nakamura, Akihisa; Yamada, Ren; Ohara, Masatsugu; Kawagishi, Naoki; Natsuizaka, Mitsuteru; Nakai, Masato; Suzuki, Kazuharu; Izumi, Takaaki; Meguro, Takashi; Terashita, Katsumi; Takagi, Tomofumi; Ito, Jun; Kobayashi, Tomoe; Miyagishima, Takuto; Sakamoto, Naoya

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.

乐伐替尼治疗期间血清生长因子的变化可预测不可切除肝细胞癌患者的进展后生存期

期刊:Cancers

影响因子:4.4

doi:10.3390/cancers14010232

Yang Zijian, Suda Goki, Maehara Osamu, Ohara Masatsugu, Yoshida Sonoe, Hosoda Shunichi, Kimura Megumi, Kubo Akinori, Tokuchi Yoshimasa, Fu Qingjie, Yamada Ren, Kitagataya Takashi, Suzuki Kazuharu, Kawagishi Naoki, Nakai Masato, Sho Takuya, Natsuizaka Mitsuteru, Morikawa Kenichi, Ogawa Koji, Ohnishi Shunsuke, Sakamoto Naoya

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

血清IL-1β水平可预测丙型肝炎直接抗病毒治疗期间乙型肝炎病毒的新生再激活，但不能预测抗癌/免疫抑制治疗期间的乙型肝炎病毒再激活。

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-022-21315-z

Kawagishi, Naoki; Suda, Goki; Sakamori, Ryotaro; Matsui, Takeshi; Onozawa, Masahiro; Yang, Zijian; Yoshida, Sonoe; Ohara, Masatsugu; Kimura, Megumi; Kubo, Akinori; Maehara, Osamu; Fu, Qingjie; Hosoda, Shunichi; Tokuchi, Yoshimasa; Suzuki, Kazuharu; Nakai, Masato; Sho, Takuya; Morikawa, Kenichi; Natsuizaka, Mitsuteru; Ogawa, Koji; Sakai, Hajime; Ohnishi, Shunsuke; Baba, Masaru; Takehara, Tetsuo; Sakamoto, Naoya

Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC.

血清 FGF21 作为预测 HCC 对阿特珠单抗和贝伐珠单抗反应的指标

Laparoscopic Low Anterior Resection for Rectal Cancer in a Patient With Rectal Varices Secondary to Metabolic Dysfunction-Associated Steatohepatitis-Related Cirrhosis: A Case Report

腹腔镜下直肠癌低位前切除术治疗代谢功能障碍相关脂肪性肝炎相关性肝硬化合并直肠静脉曲张患者：病例报告

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.

基线 CXCL9 水平低可预测接受 Atezolizumab 联合 Bevacizumab 治疗的不可切除 HCC 患者的早期疾病进展

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma

肌肉萎缩和皮下脂肪组织放射密度增高同时存在预示着肝细胞癌预后不良。

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者对阿特珠单抗联合贝伐珠单抗治疗产生耐药性期间血清生长因子的变化

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.

血清 FGF21 水平变化与 Lenvatinib 诱导的不可切除肝细胞癌患者食欲丧失之间可能存在相关性

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C

血清血管生成素-2可预测丙型肝炎直接抗病毒治疗后肝细胞癌的发生和复发。

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150

阿特珠单抗和贝伐珠单抗治疗不符合 IMbrave150 研究入组标准的不可切除肝细胞癌患者的疗效及对肝功能储备的影响

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma.

乐伐替尼治疗期间血清生长因子的变化可预测不可切除肝细胞癌患者的进展后生存期

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

血清IL-1β水平可预测丙型肝炎直接抗病毒治疗期间乙型肝炎病毒的新生再激活，但不能预测抗癌/免疫抑制治疗期间的乙型肝炎病毒再激活。